世界の過敏性腸症候群治療市場予測:2021-2028

◆英語タイトル:GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET FORECAST 2021-2028
◆商品コード:INK21MC033
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2021年2月1日
◆ページ数:226
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Multi LicenseUSD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD4,500 ⇒換算¥513,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Inkwood社の本調査レポートは、世界の過敏性腸症候群治療市場について調査・分析し、調査範囲・手法、エグゼクティブサマリー、市場動向、主要分析、種類別(下痢型IBS、便秘型IBS、混合型IBS)分析、製品別分析、流通チャンネル別分析、作用機序別分析、地域別分析、競争状況などの情報をお届けいたします。
・調査範囲・手法
・エグゼクティブサマリー
・市場動向
・主要分析
・世界の過敏性腸症候群治療市場規模:種類別(下痢型IBS、便秘型IBS、混合型IBS)
・世界の過敏性腸症候群治療市場規模:製品別
・世界の過敏性腸症候群治療市場規模:流通チャンネル別
・世界の過敏性腸症候群治療市場規模:作用機序別
・地域別分析
・競争状況
【レポートの概要】

KEY FINDINGS
The global irritable bowel syndrome treatment market is predicted to grow with a CAGR of 7.25%, during the forecast period of 2021 to 2028. The market growth is mainly fueled by factors like, the rising prevalence of gastrointestinal ailments, the increasing number of FDA approvals and drug developments, the surging occurrence of irritable bowel syndrome, and the growing geriatric population.

MARKET INSIGHTS
Irritable bowel syndrome is characterized as a gastrointestinal disorder of the gut, identified by colon muscle contraction. It primarily affects the large intestine. The condition is linked with the malfunction of the bowel and is predominantly widespread across the elderly population. Constipation, diarrhea, alteration, and discomfort in bowel function, abdominal pain, and bloating, are among the common symptoms of irritable bowel syndrome.
The rising number of FDA approvals, in addition to drug development activities, is expected to augment the global irritable bowel syndrome treatment market growth, during the forecast years. Moreover, the majority of new as well as established players are manufacturing drugs for the condition. As a result, this factor is likely to elevate the availability of the required medicines in the market. For instance, Ardelyx, Inc received the FDA approval in 2019, for its Ibsrela (tenapanor), to treat irritable bowel syndrome with constipation (IBS-C), in adults.

REGIONAL INSIGHTS
The global irritable bowel syndrome treatment market growth is evaluated by assessing North America, Europe, the Asia Pacific, and the rest of the world. The Asia Pacific is set to be the fastest-growing region over the forecast period. The market growth is accredited to improvements across the healthcare infrastructure, the growing number of hospitals equipped with advanced medical facilities, the surging healthcare reforms, and the augmenting research and development sector.

COMPETITIVE INSIGHTS
Some of the leading companies operating in the market are, Allergan PLC, GlaxoSmithKline PLC, Allergan PLC, Novartis AG, AstraZeneca PLC, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. RISE IN THE INCIDENCE OF GASTROINTESTINAL AILMENTS
3.1.2. GROWING NUMBER OF DRUG DEVELOPMENTS AND FDA APPROVALS
3.1.3. SURGING OCCURENCE OF IRRITABLE BOWEL SYNDROME
3.1.4. INCREASING GERIATRIC POPULATION
3.2. KEY RESTRAINTS
3.2.1. HIGH COST OF DRUGS
3.2.2. LACK OF SKILLED PROFESSIONALS IN DEVELOPING ECONOMIES
3.2.3. LIMITED TREATMENT OPTIONS
4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCES ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. IMPACT OF COVID-19 ON IRRITABLE BOWEL SYNDROME TREATMENT MARKET
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. KEY INVESTMENT INSIGHTS
5. MARKET BY TYPE
5.1. IBS WITH DIARRHEA
5.2. IBS WITH CONSTIPATION
5.3. MIXED IBS
6. MARKET BY PRODUCT
6.1. RIFAXIMIN
6.2. ELUXADOLINE
6.3. LINACLOTIDE
6.4. LUBIPROSTONE
6.5. OTHER PRODUCTS
7. MARKET BY DISTRIBUTION CHANNEL
7.1. DRUG STORES AND RETAIL PHARMACIES
7.2. HOSPITALS’ PHARMACIES
7.3. ONLINE PHARMACIES
8. MARKET BY MECHANISM OF ACTION
8.1. 5HT3 ANTAGONIST
8.2. GUANYLATE CYCLASE RECEPTOR-C AGONIST
8.3. CHLORIDE CHANNEL ACTIVATOR
8.4. OTHER MECHANISM OF ACTIONS
9. MARKET BY DOSAGE
9.1. SOLID
9.2. LIQUID
10. GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1. MARKET SIZE & ESTIMATES
10.1.2. KEY GROWTH ENABLERS
10.1.3. KEY CHALLENGES
10.1.4. KEY PLAYERS
10.1.5. COUNTRY ANALYSIS
10.1.5.1. UNITED STATES
10.1.5.2. CANADA
10.2. EUROPE
10.2.1. MARKET SIZE & ESTIMATES
10.2.2. KEY GROWTH ENABLERS
10.2.3. KEY CHALLENGES
10.2.4. KEY PLAYERS
10.2.5. COUNTRY ANALYSIS
10.2.5.1. GERMANY
10.2.5.2. FRANCE
10.2.5.3. UNITED KINGDOM
10.2.5.4. ITALY
10.2.5.5. RUSSIA
10.2.5.6. BELGIUM
10.2.5.7. POLAND
10.2.5.8. REST OF EUROPE
10.3. ASIA PACIFIC
10.3.1. MARKET SIZE & ESTIMATES
10.3.2. KEY GROWTH ENABLERS
10.3.3. KEY CHALLENGES
10.3.4. KEY PLAYERS
10.3.5. COUNTRY ANALYSIS
10.3.5.1. JAPAN
10.3.5.2. CHINA
10.3.5.3. AUSTRALIA & NEW ZEALAND
10.3.5.4. INDIA
10.3.5.5. SOUTH KOREA
10.3.5.6. THAILAND
10.3.5.7. INDONESIA
10.3.5.8. VIETNAM
10.3.5.9. REST OF ASIA PACIFIC
10.4. REST OF WORLD
10.4.1. MARKET SIZE & ESTIMATES
10.4.2. KEY GROWTH ENABLERS
10.4.3. KEY CHALLENGE
10.4.4. KEY PLAYERS
10.4.5. REGIONAL ANALYSIS
10.4.5.1. LATIN AMERICA
10.4.5.2. MIDDLE EAST & AFRICA
11. COMPETITIVE LANDSCAPE
11.1. KEY STRATEGIC DEVELOPMENTS
11.1.1. MERGER & ACQUISITIONS
11.1.2. PRODUCT LAUNCH & DEVELOPMENTS
11.1.3. PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
11.1.4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
11.2. COMPANY PROFILE
11.2.1. ABBOTT LABORATORIES
11.2.2. BAUSCH HEALTH COMPANIES INC
11.2.3. ALLERGAN PLC
11.2.4. ARDELYX INC
11.2.5. ASTELLAS PHARMA INC
11.2.6. ASTRAZENECA PLC
11.2.7. GLAXOSMITHKLINE PLC
11.2.8. IRONWOOD PHARMACEUTICALS INC
11.2.9. JOHNSON & JOHNSON (MCNEIL CONSUMER HEALTHCARE)
11.2.10. LANNETT COMPANY INC
11.2.11. NOVARTIS AG
11.2.12. SEBELA PHARMACEUTICALS INC
11.2.13. SYNTHETIC BIOLOGICS INC
11.2.14. TAKEDA PHARMACEUTICAL COMPANY LTD

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - IRRITABLE BOWEL SYNDROME TREATMENT
TABLE 2: NUMBER OF PERSONS AGED 65 YEARS OR OVER BY GEOGRAPHIC REGION, 2019 AND 2050
TABLE 3: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 4: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 5: GLOBAL IBS WITH DIARRHEA MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 6: GLOBAL IBS WITH DIARRHEA MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 7: GLOBAL IBS WITH CONSTIPATION MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 8: GLOBAL IBS WITH CONSTIPATION MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 9: GLOBAL MIXED IBS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 10: GLOBAL MIXED IBS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 11: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 12: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 13: GLOBAL RIFAXIMIN MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 14: GLOBAL RIFAXIMIN MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 15: GLOBAL ELUXADOLINE MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 16: GLOBAL ELUXADOLINE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 17: GLOBAL LINACLOTIDE MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 18: GLOBAL LINACLOTIDE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 19: GLOBAL LUBIPROSTONE MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 20: GLOBAL LUBIPROSTONE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 21: GLOBAL OTHER PRODUCTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 22: GLOBAL OTHER PRODUCTS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 23: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 24: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 25: GLOBAL DRUG STORES AND RETAIL PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 26: GLOBAL DRUG STORES AND RETAIL PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 27: GLOBAL HOSPITALS’ PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 28: GLOBAL HOSPITALS’ PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 29: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 30: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 31: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 32: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 33: GLOBAL 5HT3 ANTAGONIST MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 34: GLOBAL 5HT3 ANTAGONIST MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 35: GLOBAL GUANYLATE CYCLASE RECEPTOR-C AGONIST MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 36: GLOBAL GUANYLATE CYCLASE RECEPTOR-C AGONIST MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 37: GLOBAL CHLORIDE CHANNEL ACTIVATOR MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 38: GLOBAL CHLORIDE CHANNEL ACTIVATOR MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 39: GLOBAL OTHER MECHANISM OF ACTIONS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 40: GLOBAL OTHER MECHANISM OF ACTIONS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 41: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 42: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 43: GLOBAL SOLID MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 44: GLOBAL SOLID MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 45: GLOBAL LIQUID MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 46: GLOBAL LIQUID MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 47: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 48: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 49: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 50: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 51: LEADING PLAYERS OPERATING IN NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET
TABLE 52: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 53: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 54: LEADING PLAYERS OPERATING IN EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET
TABLE 55: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 56: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 57: LEADING PLAYERS OPERATING IN ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET
TABLE 58: REST OF WORLD IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 59: REST OF WORLD IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 60: LEADING PLAYERS OPERATING IN REST OF WORLD IRRITABLE BOWEL SYNDROME TREATMENT MARKET


LIST OF FIGURES
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: OPPORTUNITY MATRIX
FIGURE 3: VENDOR LANDSCAPE
FIGURE 4: KEY INVESTMENT INSIGHTS
FIGURE 5: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, IN 2020
FIGURE 6: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH DIARRHEA, 2021-2028 (IN $ MILLION)
FIGURE 7: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH CONSTIPATION, 2021-2028 (IN $ MILLION)
FIGURE 8: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MIXED IBS, 2021-2028 (IN $ MILLION)
FIGURE 9: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, IN 2020
FIGURE 10: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY RIFAXIMIN, 2021-2028 (IN $ MILLION)
FIGURE 11: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ELUXADOLINE, 2021-2028 (IN $ MILLION)
FIGURE 12: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LINACLOTIDE, 2021-2028 (IN $ MILLION)
FIGURE 13: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LUBIPROSTONE, 2021-2028 (IN $ MILLION)
FIGURE 14: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER PRODUCTS, 2021-2028 (IN $ MILLION)
FIGURE 15: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, IN 2020
FIGURE 16: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DRUG STORES AND RETAIL PHARMACIES, 2021-2028 (IN $ MILLION)
FIGURE 17: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY HOSPITALS’ PHARMACIES, 2021-2028 (IN $ MILLION)
FIGURE 18: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ONLINE PHARMACIES, 2021-2028 (IN $ MILLION)
FIGURE 19: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, IN 2020
FIGURE 20: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY 5HT3 ANTAGONIST, 2021-2028 (IN $ MILLION)
FIGURE 21: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY GUANYLATE CYCLASE RECEPTOR-C AGONIST, 2021-2028 (IN $ MILLION)
FIGURE 22: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY CHLORIDE CHANNEL ACTIVATOR, 2021-2028 (IN $ MILLION)
FIGURE 23: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER MECHANISM OF ACTIONS, 2021-2028 (IN $ MILLION)
FIGURE 24: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, IN 2020
FIGURE 25: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY SOLID, 2021-2028 (IN $ MILLION)
FIGURE 26: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LIQUID, 2021-2028 (IN $ MILLION)
FIGURE 27: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
FIGURE 28: UNITED STATES IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 29: CANADA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 30: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
FIGURE 31: GERMANY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 32: FRANCE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 33: UNITED KINGDOM IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 34: ITALY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 35: RUSSIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 36: BELGIUM IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 37: POLAND IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 38: REST OF EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 39: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
FIGURE 40: JAPAN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 41: CHINA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 42: AUSTRALIA & NEW ZEALAND IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 43: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 44: SOUTH KOREA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 45: THAILAND IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 46: INDONESIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 47: VIETNAM IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 48: REST OF ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 49: REST OF WORLD IRRITABLE BOWEL SYNDROME TREATMENT MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)
FIGURE 50: LATIN AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 51: MIDDLE EAST & AFRICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の過敏性腸症候群治療市場予測:2021-2028]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆